Eli Lilly and Co (LLY)
749.91
-3.50
(-0.46%)
USD |
NYSE |
Nov 21, 16:00
748.60
-1.31
(-0.17%)
After-Hours: 17:11
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 711.90B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 26.89% |
| Valuation | |
| PE Ratio | 81.07 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 16.59 |
| Price to Book Value | 49.99 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.30 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 2.185 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 22.48% |
Profile
| Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
| URL | https://www.lilly.com |
| Investor Relations URL | https://investor.lilly.com/ |
| HQ State/Province | Indiana |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 30, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 15, 2024 |
Ratings
Profile
| Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
| URL | https://www.lilly.com |
| Investor Relations URL | https://investor.lilly.com/ |
| HQ State/Province | Indiana |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Apr. 30, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 15, 2024 |